Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 9NIH 7INDUSTRY 5NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1

Conditions

Breast Neoplasms 265Leukemia 183Carcinoma, Non-Small-Cell Lung 168Lymphoma 159Lung Neoplasms 148Prostatic Neoplasms 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 130Ovarian Neoplasms 117Colorectal Neoplasms 115Sarcoma 108Central Nervous System Neoplasms 107Head and Neck Neoplasms 98Leukemia, Myeloid, Acute 95Multiple Myeloma 93Squamous Cell Carcinoma of Head and Neck 83Rectal Neoplasms 77Colonic Neoplasms 71Uterine Cervical Neoplasms 65Neoplasm Metastasis 65Neuroblastoma 64Carcinoma, Ovarian Epithelial 64Brain Neoplasms 64Neoplasms 63Fallopian Tube Neoplasms 62Lymphoma, Large B-Cell, Diffuse 61Astrocytoma 59Melanoma 58Leukemia, Lymphocytic, Chronic, B-Cell 56Burkitt Lymphoma 56Hodgkin Disease 55

Interventions

Octreotide 2vatalanib 1motesanib diphosphate 1batifiban 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Vipoma × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡